Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Applebaum

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Biorxiv : the Preprint Server for Biology|February 12, 2026
Histotripsy-initiated immune response synergizes with chemotherapy in a neuroblastoma murine modelNatalia Antonides-Jensen, Muskan Singh, Yuqing Xue, et al.
Cancers|May 4, 2026
Histotripsy-Initiated Immune Response Synergizes with Chemotherapy in a Neuroblastoma Murine ModelNatalia Antonides-Jensen, Muskan Singh, Yuqing Xue, et al.
Journal of the National Cancer Institute|November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified NeuroblastomaEric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 13, 2023
Diffuse Pediatric-type High-grade Glioma Arising in an Ovarian Mature Cystic TeratomaLena Elmuti, Julia Amundson, Elise Oberman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 11, 2024
Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunityYan-Hong Cui, Jiangbo Wei, Hao Fan, et al.
Annals of Surgical Oncology|March 10, 2016
Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary?Matthew P Doepker, Zachary J Thompson, Kate J Fisher, et al.
Clinical and Translational Science|June 11, 2026
A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in NeuroblastomaLin Xu, Arhanti Sadanand, Evan W Neczypor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG ProjectElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Reply to K. Beiske et alElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Biorxiv : the Preprint Server for Biology|February 12, 2026
Histotripsy-initiated immune response synergizes with chemotherapy in a neuroblastoma murine modelNatalia Antonides-Jensen, Muskan Singh, Yuqing Xue, et al.
Cancers|May 4, 2026
Histotripsy-Initiated Immune Response Synergizes with Chemotherapy in a Neuroblastoma Murine ModelNatalia Antonides-Jensen, Muskan Singh, Yuqing Xue, et al.
Journal of the National Cancer Institute|November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified NeuroblastomaEric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 13, 2023
Diffuse Pediatric-type High-grade Glioma Arising in an Ovarian Mature Cystic TeratomaLena Elmuti, Julia Amundson, Elise Oberman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 11, 2024
Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunityYan-Hong Cui, Jiangbo Wei, Hao Fan, et al.
Annals of Surgical Oncology|March 10, 2016
Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary?Matthew P Doepker, Zachary J Thompson, Kate J Fisher, et al.
Clinical and Translational Science|June 11, 2026
A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in NeuroblastomaLin Xu, Arhanti Sadanand, Evan W Neczypor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG ProjectElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Reply to K. Beiske et alElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pageof 13